Humana Inc. (NYSE: HUM) — The Trough Trade Already Printed

Sector: Health Care / Managed Health Care (GICS) — pure-play Medicare Advantage Prepared: June 6, 2026 Price at writing: ~$350.08 (2026-06-05) · Market cap: ~$42B · Shares: ~120M · CIK: 0000049071 · FYE: Dec 31 · CEO: Jim Rechtin (since July 2024)

Standing disclaimer — the analysis that follows (the numbered sections below) deliberately takes no investment recommendation and states no price target. The single, fenced-off exception is the Claude's Take block immediately below, which is a clearly-labeled, independent opinion.

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is general information, not investment advice. Everything from the Executive Summary onward carries no recommendation and no price target.

Verdict: HOLD at ~$350 — a great trade that already happened. Accumulate only on weakness back toward the high-$200s/low-$300s; not a short. Directional zone: the defensible value band is roughly $300–$375 on a base-case normalized EPS of ~$22–27 at a 13–15x managed-care multiple; you got paid to be greedy at $185, not at $350.

Tag: “The trough trade already printed — at $350 you’re buying the recovery, not the discount.”

Here is the framing, and it is momentum-meets-mean-reversion, not deep value anymore. Six months ago Humana was a textbook contrarian falling-knife-turned-bargain: a high-quality #2 Medicare Advantage franchise priced as if a cyclical-plus-idiosyncratic earnings collapse (post-COVID utilization, a soft 2025 rate year, a self-inflicted Star-ratings cliff, the v28 risk-model phase-in) were permanent. The market threw it to ~$185 in early 2026 — and, tellingly, the new CEO bought $1.5M of stock at $229 and the CenterWell president bought at $185 into that decline, with essentially zero insider selling across a 60% drawdown. That was the convex moment. The stock has since roughly doubled to ~$350 (+30.6% since the last print, +6% on June 4 alone on “softer cost trends”), and the easy, asymmetric money has been made. The sell-side consensus target (~$269) now sits below the share price — the tape outran the analysts. At $350 the base case (normalized EPS ~$22–27, value ~$300–375) brackets the current price: you are now underwriting a near-full return to structurally-re-rated prior-peak earnings power by ~2028, with the Star-ratings drag not even beginning to lift until the 2027 payment year. That is a recovery priced as largely assured, on a business with a partial moat (local MA scale, real; but management itself concedes “barriers to entry are not substantial” and seniors switch freely every year), ~83% of premium from a single buyer (CMS) that is actively harvesting the industry’s margin, and the least diversification of any major (no Optum, no commercial book, CenterWell still <10% of members and more option than moat).

Conviction: medium. What flips me bullish again: a clean, sustained benefit-ratio inflection below ~88% in 2026–27 plus visible Star-ratings recovery for PY2027 (back toward >50% of members in 4+ star plans) — that would validate normalized EPS pushing toward $30 and re-open upside to the $450–600 bull zone. What flips me bearish: benefit ratio sticky at ~90%+ into 2027, a re-promulgated RADV extrapolation/coding clawback, or a soft 2027 CMS rate notice — any of which exposes the back-end-loaded recovery and re-rates the stock back toward the $200s, where the bear scenario lives. I’d rather own this on the next disappointment than chase the rebound.

1. Executive Summary

Humana is the purest large-cap bet in US managed care on a single proposition: that Medicare Advantage (MA) margins normalize after a brutal 2023–2026 down-cycle. It is the #2 MA insurer (~17–18% national share, largest or second-largest in two-thirds of US counties), with ~83% of premium revenue paid by the federal government and ~70% of consolidated revenue from individual MA alone. That concentration is the entire story — both the franchise and the fragility.

The business is in a genuine earnings trough. GAAP diluted EPS fell from $20.00 (FY2023) to $9.98 (FY2024, −50%) to $9.84 (FY2025) as the consolidated benefit (medical-loss) ratio climbed from 87.3% → 89.8% → 90.2%. Four forces hit at once: (1) post-COVID senior utilization running above pricing; (2) a soft 2025 CMS rate year; (3) the CMS-HCC v28 risk-adjustment model phasing in (33%→67%→100% across PY2024–26), structurally compressing risk scores; and (4) a self-inflicted Star-ratings collapse — the share of Humana MA members in 4+ star (bonus-earning) plans fell from ~94% to ~25% to ~20% across payment years 2024→2025→2026, a $1–3B revenue headwind that does not begin to recover until PY2027 at the earliest. Management responded by deliberately shrinking — exiting unprofitable plans/counties and shedding ~7.3% of individual MA members in 2025 to protect margin — then guiding to a volume rebound (+~25%) for 2026 that is margin-dilutive in year one.

The verdict on the franchise is nuanced and, on balance, cautious. The industry is structurally average-and-deteriorating: superb secular demand (MA is now 54% of eligible Medicare, heading toward ~64% by 2034) captured by a single monopsony buyer (CMS) that sets rates, writes the risk model, arbitrates Stars, and is — per MedPAC — trying to claw back ~$84B/year of estimated MA “overpayment.” The moat is partial: real local-scale cost/contracting advantage, but no member captivity (annual free switching), CenterWell still sub-scale versus UnitedHealth’s Optum, and Stars flipped from an edge to a liability. Financial quality is a cyclical impairment, not a structural one — normalized ROE returns toward the mid-teens from a ~7% trough — but the reported “stabilization” in FY2025 was lower-quality than it looks (flattered by a tax-rate drop to 17.4%, ~$1.0B of favorable prior-year reserve development, and adjusted-EPS add-backs of $7.38/share, ~75% of GAAP EPS). Capital allocation has been below-average over the cycle (buybacks concentrated at the 2023–24 peak then paused at the bottom; the 2021 Kindred home-health deal at an $8.2B peak EV; a large WCAS put/call contingent liability on the CenterWell JV) but is improving under new CEO Jim Rechtin, whose own open-market buying and a redesigned incentive plan (Stars + relative TSR) are constructive signals.

The crux is valuation. The stock has roughly doubled off its ~$185 early-2026 low to ~$350, converting Humana from “trough priced as permanent” into “recovery priced as largely assured.” At ~$42B market cap, the embedded expectation is a normalized EPS of roughly $22–27 — above the FY2023 pre-trough peak ($20 GAAP), well above FY2027 consensus (~$15), and ~35% below management’s old ~$37 aspiration. The market is, in this read, correct that FY2026 is the earnings trough and the cyclical piece of the recovery is real, but is leaning hard on a back-end-loaded (2028) recovery and may be under-weighting the ~40% of the margin compression that is structural and permanent (v28, Stars, IRA, coding clawback). This memo takes no position and sets no price target; it lays out the embedded expectations and the scenario zones so the reader can judge the risk/reward at today’s price.

2. Business Overview

2.1 What Humana does

Humana Inc. is a health-and-well-being company organized, since a 2023 restructuring, into two reportable segments:

(1) Insurance — the core, ~96% of consolidated revenue. This is a health-benefits underwriter overwhelmingly concentrated in government programs for seniors:

• Individual Medicare Advantage (MA) — the dominant product. Humana contracts with the Centers for Medicare & Medicaid Services (CMS) to administer Medicare benefits for seniors who choose a private MA plan over traditional fee-for-service (FFS) Medicare. CMS pays Humana a risk-adjusted, per-member-per-month (PMPM) capitated rate; Humana bears the medical-cost risk. Individual MA alone was ~70.3% of consolidated revenue (~$90.4B) in FY2025.
• Group MA — employer/union-sponsored MA plans.
• Standalone Medicare Part D prescription-drug plans (PDP) — drug-only coverage; economics reshaped by the Inflation Reduction Act (IRA) Part D redesign.
• Medicaid — state contracts (managed Medicaid, dual-eligible special-needs plans).
• Specialty — dental, vision, life and disability.
• TRICARE — administrative services for the military health system (the East Region contract); fee-based, not at-risk.
• Medicare Supplement — supplemental coverage to traditional Medicare.

Total Medicare (individual + group MA + PDP) was ~82.6% of consolidated revenue in FY2025; ~83% of premium comes from the federal government — the defining concentration of the business.

(2) CenterWell — the value-based healthcare-services arm and the strategic growth bet, ~3.7% of external revenue (but ~$22.5B of total/largely intersegment revenue in FY2025). Three pieces:

• CenterWell / Conviva senior-focused primary care — ~350 value-based (capitated) clinics, ~1,300 primary-care physicians, serving ~491,000 patients (note: <10% of Humana’s own ~5.2M individual-MA members). Part of this is a JV with private-equity firm Welsh, Carson, Anderson & Stowe (WCAS) — 146 clinics — carrying material put/call options (see section 7).
• CenterWell Home Health — one of the largest US home-health providers, built principally from the 2021–22 Kindred at Home acquisition.
• CenterWell Pharmacy — mail-order and specialty pharmacy, recently expanding capacity (a new mail-order facility was a June 2026 news item).

2.2 How it makes money

Humana’s economics are an underwriting spread. In MA, CMS pays a capitated benchmark, adjusted up for member health-risk scores (the risk-adjustment model) and for plan quality (the Star-ratings quality bonus — plans rated 4.0 stars or higher earn roughly a 5% benchmark bonus plus richer rebates that fund member benefits). Humana keeps the difference between that risk-and-quality-adjusted revenue and the medical claims it pays, less administrative cost. The two ratios that govern profitability are therefore:

• Benefit ratio (medical-loss ratio, MLR) = medical claims ÷ premium revenue. At ~85% of total cost, this is “the whole ballgame.” Consolidated FY2025: 90.2%.
• Operating cost ratio (SG&A leverage) — secondary, but matters at scale.

CenterWell adds a second, structurally different margin: by owning the primary-care, home-health, and pharmacy assets that treat MA members, Humana captures part of the medical-cost dollar it would otherwise pay out — the “payvider” flywheel that UnitedHealth pioneered with Optum.

2.3 Recurring vs. non-recurring

Revenue is highly recurring at the aggregate level — MA is an annual, auto-renewing entitlement product with a large installed base. But it is not sticky at the member level: the Medicare Annual Enrollment Period (AEP, mid-October to early December) lets every senior switch plans, for free, every year. Retention is a function of price, benefit richness, and network — not lock-in. This is the central tension of the franchise (see section 4).

Verdict: A simple, understandable, recurring-revenue government-benefits underwriter with a fast-growing but still-small owned-care-delivery arm. The model is clean; the risk is that virtually all of it depends on the pricing and rules of one counterparty (CMS) and on a member base that re-shops annually.

3. Industry Dynamics

3.1 Market structure and size — superb demand

Medicare Advantage is one of the best demand stories in US healthcare. MA penetration has risen from 19% of eligible Medicare in 2007 to 54% in 2025 (34.1M of ~62.8M Part A&B enrollees), and the CBO projects ~64% by 2034. The driver is demographic and durable: ~10,000 Americans age into Medicare daily, and a majority now choose a private MA plan — drawn by lower premiums, out-of-pocket caps, and extra benefits (dental, vision, OTC allowances) that traditional Medicare lacks. This is a multi-decade tailwind.

But growth is decelerating and the profit pool is being squeezed. YoY MA enrollment growth slowed to ~4% (2024→2025) from ~7% prior, and the gross margin per MA enrollee fell from ~$1,982 (2023) to ~$1,655 (2024), down ~16% (KFF), with sector MA MLR around ~90% in 2024 — matching Humana’s 90.2%. MA remains the highest-margin insurance line (vs. ~$753/enrollee Medicaid), which is precisely why every major plays in it and why CMS is now targeting it.

3.2 Concentration — a local oligopoly

MA is a two-firm national oligopoly with deep local concentration. UnitedHealth (~29%) + Humana (~17–18%) ≈ 46–47% of national MA enrollment; at the county level, UNH or Humana holds the largest share in roughly two-thirds of counties, and 9 in 10 MA enrollees live in markets where one or two insurers cover ≥50% of MA members (KFF). This local density is a genuine source of cost and contracting advantage (network depth, provider leverage, Star-operations scale) — but, crucially, it is not pricing power, because the price is set by CMS.

3.3 Who holds the power — CMS as monopsony

The dominant structural fact is buyer power. CMS is simultaneously the monopsony buyer, the rate-setter (annual benchmark “Rate Announcements”), the author of the risk-adjustment model (v28), the arbiter of plan quality (Star ratings), the coding-intensity adjuster, and the auditor (RADV). With ~83% of Humana’s premium flowing from this single counterparty, insurer pricing power in MA is near zero. In Greenwald/Porter terms, this is an industry where the buyer captures the surplus and the most valuable insurer capability — risk-score (coding) intensity — is exactly what the buyer is dismantling.

3.4 The 2023–2026 down-cycle: cyclical vs. structural

This is the analytical crux. The simultaneous margin compression decomposes (~60% cyclical / ~40% structural):

The conclusion: the cycle reprices (and 2026’s strong rate + supply discipline should help survivors into 2027–28), but the structural re-rating does not reverse — through-cycle MA margins are being reset to a permanently lower band.

3.5 Capital-cycle read

Classic late-bust / early-recovery. Capital was over-attracted to MA in 2020–23 (margin peak, plan proliferation to ~3,719 plans, ever-richer benefits) — a textbook boom. Supply is now exiting: UNH exiting ~225 counties, Humana ~198 for 2026; national plan count down ~10% (3,719→3,373); ~2.6–2.9M enrollees in terminated plans. Supply contraction plus benefit discipline plus the strong 2026 rate should support survivor margin recovery — but the policy-breakdown caveat bites hard here: the regulator can harvest the upturn via lower future rates or deeper coding cuts the moment profitability visibly recovers. The recovery is capped from above by the same monopsony that caused the bust.

3.6 Vertical integration — the one defensible moat

Because insurers cannot control the CMS-set revenue line, the only durable cost/scale advantage in the sector is owning care delivery — Optum (UNH), Carelon (Elevance), CenterWell (Humana). The structural evidence treats vertical integration as having moved from “option” to “competitive necessity,” especially as CMS restricts prior authorization (removing a cost lever). Humana’s CenterWell is the right strategy but materially sub-scale versus Optum.

Verdict: Structurally average-and-deteriorating as an industry (great demand, captured by a single regulated buyer running a margin-extraction program; a constructive supply-side cycle whose fruits the regulator can reclaim). For a pure-play like Humana, structurally poor / disadvantaged — maximum exposure to every structural lever, the worst Star collapse in the group, sub-scale vertical integration, and near-zero pricing power. “Great demand, captured by a single buyer who has decided to take the margin back — and the pure-play has nowhere to hide.”

4. Competitive Position

4.1 Naming the moat

The honest answer is that Humana has a partial local-scale advantage and little else — and management says so. The FY2025 10-K Risk Factors state, verbatim, that “barriers to entry in our markets are not substantial… and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period.” That is an admission against interest, and it is correct.

• Scale economies (local): REAL but partial. As the #1-or-#2 insurer in two-thirds of counties, Humana has genuine local density advantages — provider-network depth, contracting leverage, fixed-cost absorption across Star operations and data/coding infrastructure, and proprietary data on senior cost patterns. The “think local” lens validates this: managed care is won county by county, and density there is defensible. But scale only becomes a moat when paired with customer captivity — and that leg is missing.
• Switching costs / captivity: ABSENT. Seniors re-shop every AEP at zero cost. There is no contractual lock-in, no data lock-in, no meaningful friction. Retention is bought with benefits and price, not protected by switching costs.
• Network effects: NONE in any rigorous sense.
• Brand / intangibles: WEAK-TO-MODERATE. The Humana brand and CMS contracts have value, but neither prevents a member from switching or a competitor from entering a county.
• Regulatory “moat”: double-edged. Star ratings could be a quality moat — but Humana’s collapse to ~20% of members in 4+ star plans turned it into a fragility, not a barrier.

4.2 CenterWell — option, not yet a moat

The vertical-integration flywheel is strategically correct and the genuine long-term moat candidate, but today it is sub-scale: ~350 clinics, ~1,300 PCPs, ~491k patients (<10% of Humana’s individual-MA members), with segment income from operations flat YoY at ~$1.34B in FY2025 and the operating-cost ratio rising ~90bps under v28 drag. For scale comparison, Optum fields >90,000 affiliated/employed physicians and targeted +650k value-based patients in 2025 alone. External primary-care revenue grew +76% YoY — real momentum — but CenterWell is not yet an enterprise-level cost advantage. It is a valuable option on becoming one.

4.3 Competitive ranking

Humana is the most MA-levered and least-diversified of the majors — maximum torque to MA economics in both directions.

4.4 Share-stability and capital-cycle tests

Humana fails the share-stability test that a true moat would pass: individual MA membership ran 5.41M → 5.66M → 5.25M (−7.3% in FY2025) → +22.6% YoY by Q1 2026 — high-teens-percent swings in 24 months, partly self-inflicted (the deliberate prune) but inconsistent with a captive base. The capital-cycle read is more favorable: the supply-side cycle now favors disciplined incumbents, and Humana is a clear survivor — though its own +25% 2026 growth guide cuts against the discipline thesis and re-imports lower-margin volume.

Verdict: A structurally vulnerable MA pure-play with a partial #2-incumbent local-scale advantage — not a wide moat. Weak captivity, CenterWell still option-not-moat, Stars a current fragility, zero diversification. The positive is timing (a favorable capital cycle for disciplined survivors), not durable advantage. This is a margin-recovery turnaround on a partial-moat asset, not a quality compounder being bought at a discount.

5. Growth History and Forward Opportunities

5.1 Historical growth

Top-line growth has been steady and acquisition-aided: total revenue $106.4B (FY2023) → $117.8B (FY2024, +10.7%) → $129.7B (FY2025, +10.1%). But the FY2025 figure is partly optical — the IRA Part D redesign grosses up reported premium (insurers now book gross subsidies), so underlying premium growth is lower than the headline, and Q1 2026 revenue of $39.6B is inflated by the same mechanic. Strip the accounting and the real engine has been MA membership growth plus rate, until the 2025 reversal.

Membership tells the truer story: individual MA grew 5.41M → 5.66M in FY2024, then deliberately shrank 7.3% to 5.25M in FY2025 as management exited unprofitable counties and pruned benefit-rich, money-losing plans to defend margin. That prune was high-quality: despite fewer members, Insurance-segment income from operations rose ~29% to ~$1.7B. The Q1 2026 rebound (+22.6% YoY, with full-year guidance ~+25%) is the opposite — volume-led and margin-dilutive in year one, because new members run a higher benefit ratio before they season.

5.2 Forward opportunities

• MA secular growth — the demographic tailwind continues (penetration → ~64% by 2034); Humana participates as a top-2 incumbent.
• Margin recovery — the dominant value driver is not volume but the path of the benefit ratio back toward the high-80s and the individual-MA pretax margin back toward management’s ~3% target from the depressed trough.
• Star-ratings recovery — a green shoot: 14% of members moved into 4.5+ star plans for 2026 (up from 3%); a broader recovery for PY2027 would restore $1–3B of bonus revenue. This is the single biggest idiosyncratic swing factor.
• CenterWell scaling — clinic count, patient panel, and the % of Humana members served all have long runways; success would convert an option into a real cost moat.
• PDP, Medicaid, specialty, TRICARE — smaller adjacencies; Medicaid offers diversification but at much lower margin.

Verdict: Growth quality is mixed and turnaround-stage, not compounding. The 2025 shrink-to-fix was the right, high-quality move; the 2026 grow-back is lower-quality. The real “growth” that matters is margin recovery, not membership — and that is a 2026–2028 story with a structural ceiling.

6. Financial Quality

6.1 Revenue and the benefit ratio

The single most important number is the consolidated benefit (medical-loss) ratio: 87.3% (FY2023) → 89.8% (FY2024, +250bps) → 90.2% (FY2025, +40bps), with the Insurance segment at 88.0% → 90.4% → 90.4% (flat in FY2025). Q1 2026 came in at 89.4% versus 87.0% in Q1 2025 (+240bps YoY) — confirming the recovery is multi-year, not done. (The FY2024 89.8%/+250bps figure reconciles exactly to the 10-K MD&A.)

FY2025 was not a clean recovery. The consolidated ratio actually rose 40bps, driven by adverse mix (higher-MLR Medicaid and PDP, the IRA Part D hit, and lost operating leverage from the −7.3% MA membership), only partially offset by MA repricing and plan exits.

6.2 Earnings — the trough and its quality

GAAP diluted EPS: $20.00 (FY2023) → $9.98 (FY2024, −50.1%) → $9.84 (FY2025); TTM ~$9.37. The ~50% FY2024 collapse is confirmed. Operating margin compressed from ~3.8% to ~2.1% (FY2023→FY2025).

Two earnings-quality flags to weigh heavily:

1. FY2025 net income (~$1.19B, roughly flat YoY) was flattered, not genuinely stable. The effective tax rate fell from 25.5% to 17.4% (a one-off benefit from the commercial-business-exit tax loss), and ~80bps of benefit ratio (~$1.0B; FY2025 favorable prior-year reserve development was $1,029M) came from releasing prior-year reserves. Ex-development, the FY2025 underwriting benefit ratio was closer to ~91.0% — worse than reported. Underlying underwriting deteriorated YoY; the headline masked it.

2. The “adjusted” EPS is low-quality and load-bearing. Adjusted-EPS add-backs grew to $7.38/share in FY2025 (~75% of GAAP EPS) — comprising put/call (WCAS) valuation marks ($4.25, non-cash), recurring “value creation initiatives” restructuring ($3.72), and rising impairments ($2.09). The restructuring charge has been added back every year for four years ($436M / $281M / $449M for 2023/24/25) — which makes it operating in nature, not one-time. Implied adjusted EPS (~$14.91 FY2024 / ~$17.14–17.22 FY2025) should be discounted; GAAP is the honest spine.

6.3 Cash flow

Operating cash flow was $3,981M / $2,966M / $921M (FY2023/24/25). The FY2025 collapse looks alarming but is largely a CMS-payment-timing (float) and reserve-runoff artifact, not a cash-earnings collapse — do not apply an FCF framing to an insurer. Capex is modest (~$0.5B, CenterWell clinic build-out). More important for capital return: subsidiary dividends upstreamed to the parent are declining — $1.8B → $1.5B → $1.1B (FY2023/24/25) — directly constraining buybacks and dividends at the holding company.

6.4 Balance sheet and reserves

• Equity $16.3B / $16.4B / $17.7B (→$18.6B Q1 2026); book value ~$155/share. Critically, goodwill + intangibles (~$10.5B, mostly Kindred/CenterWell) make tangible book roughly half of stated book — so P/TBV (~4.5x), not P/B, is the honest equity multiple, and it is not cheap.
• Debt LT $11.1B → $12.4B; gross debt/EBITDA ~3.6x; actual debt/cap ~41% (the 60% figure is a covenant ceiling, not a target); revolver amended May 2025 to a 5-year/$5.0B facility. New debt is pricier (6.625% coupon in 2026 vs. ~5.75% in 2023).
• Statutory capital ~$14.1B vs. ~$6.9B regulatory minimum — strong excess. This is a margin/earnings problem, not a solvency problem.
• Reserves benefits payable $10.24B / $10.44B / $9.97B; computed days-claims-payable fell from ~42 to ~33 days over two years — a thinning cushion that raises forward-surprise risk if cost trend re-accelerates, even as favorable prior-year development has propped up reported margins. Lower-quality stabilization than the headline suggests.

6.5 Returns

ROE: ~15.8% (FY2023) → ~7.4% (FY2024) → ~7.0% (FY2025); TTM ~6.3%. ROIC is not meaningful for an insurer (float/regulatory capital distort the denominator). The entire bull case is normalization: at a high-80s benefit ratio, ROE returns toward the mid-teens.

Verdict: The economics are cyclically impaired, not structurally broken — a high-teens-ROE franchise earning ~7% at a trough. But the reported FY2025 “stabilization” is lower-quality than it looks (tax-rate help, reserve releases, thinning DCP, aggressive adjusted-EPS add-backs), and Q1 2026 shows the benefit ratio still rising YoY. Quality improves with scale and normalization — but the honest read underwrites GAAP, discounts management’s adjusted figure, and watches reserve adequacy.

7. Capital Allocation

7.1 The track record — below-average over the cycle

• Buybacks, badly timed. Cumulative FY2021–25 repurchases were ~$4.7B, heaviest at the top: FY2023 ~3.1M shares @ ~$483, FY2024 ~1.9M @ ~$385 — then collapsing to FY2025 ~0.4M @ ~$234 and effectively pausing, with ~$2.7B of authorization unused, just as the stock bottomed near $185. Bought high, paused at the bottom — value-destructive sequencing, and the sharpest mark against management.
• Dividend. Frozen at $0.8850/quarter (~$3.54/year, ~1% yield) since 2024 — conservative, consistent with the constrained subsidiary upstreaming.
• M&A is mixed-to-poor. The 2021 Kindred at Home buy-in (remaining 60% at an ~$8.2B EV at a home-health peak) has produced recurring impairments; the retained ~35% Gentiva Hospice stake is loss-making (−$84M FY2025). Offsetting wins: the 2022 sale of 60% of Gentiva (~$2.7B, $237M gain) was a good harvest, and the 2025 commercial-employer-group exit ($67M loss) was disciplined strategic narrowing.
• The MaxHealth tuck-in (Feb 2026, ~$908M cash, ~$800M goodwill ≈ 88% of price) doubles down on CenterWell into the trough — a notable goodwill bump at Q1 2026.

7.2 The WCAS contingent liability — underappreciated

The CenterWell primary-care JV with WCAS (146 clinics) carries put/call options that are a large, market-timing-sensitive contingent quasi-acquisition liability: Humana holds a 2026 call on the first cohorts (~$1.0–1.5B), but across all cohorts the position is callable 2026–2033 and puttable to Humana 2027–2034 — potentially requiring $3.0–5.0B. WCAS can force the buyout on Humana in a down market, exactly when capital is scarcest. The annual put/call valuation marks are also what inflate the adjusted-EPS add-backs (see section 6.2).

7.3 Incentives and alignment

The 2026 proxy is a mixed but improving picture. The annual incentive (AIP) is 70% Adjusted EPS (target $37.00) + 30% strategic, with a relative-TSR modifier; 2025 paid 48% of target (the financial component paid 0% as adjusted EPS came in ~$17.14). The weakness: the dominant metric is the gameable adjusted EPS (with its $7.38 of add-backs). The improvement: the 2025 long-term incentive was redesigned to relative TSR 50% / Stars 30% / productivity 20% — explicitly rewarding the right things (quality and shareholder outcomes). Insider ownership is trivial (~0.20% as a group; the CEO is below his 7x-salary guideline) — a genuine alignment weakness — but insider behavior into the drawdown was constructive (see section 8).

7.4 Philosophy shift under Rechtin

There is a visible pivot under CEO Jim Rechtin (since July 2024): margin over membership, deleveraging discipline, buyback restraint while subsidiary cash is constrained, and a redesigned, quality-weighted LTI. The balance sheet, however, cannot comfortably fund the turnaround, the WCAS call, and meaningful capital return simultaneously — capital return is likely to stay muted until margins and subsidiary dividends recover.

Verdict: Below-average over the cycle, improving recently. Three real marks against (buyback mistiming, the Kindred peak-price bet, the WCAS contingent put), offset by the Gentiva harvest, the disciplined commercial exit, liability management, covenant headroom, and the post-2024 pivot. Trajectory beats track record — but a quality-compounder premium is not warranted for a management team whose capital-allocation record is, at best, mid-pack.

8. Changes and Headwinds — Last Two Years

A near-complete reset of leadership, strategy, and earnings power:

• CEO transition — Bruce Broussard (CEO since 2013) handed to Jim Rechtin (President & CEO, July 2024), accompanied by a near-total C-suite refresh (new CFO/CHRO/CIO/MA-president, per the Form 3 corpus).
• The Star-ratings collapse (Oct 2024) — the seismic event. Members in 4+ star plans fell ~94%→25% (PY2024→PY2025), with the key contract H5216 dropping 4.5★→3.5★. Humana sued CMS to vacate the 2025 ratings and lost twice; CMS denied the appeal. A $1–3B revenue/benefit headwind that hits 2026 hardest and does not begin to recover until PY2027.
• Serial guidance walk-downs — GAAP EPS guidance was cut repeatedly through both 2024 (~$14.87→$12.81) and 2025 (~$15.88→$12.26), then rebased to ~$9 adjusted for 2026. The 8-K timeline reads as a textbook earnings-trough.
• Failed Cigna merger talks (late 2023) — press-reported, no captioned 8-K; the two walked away on price/structure.
• Deliberate MA membership prune (2025) and the commercial-employer-group exit (2025) — strategic narrowing toward government/senior care.
• v28 risk-model phase-in completing (PY2026), and the IRA Part D redesign reshaping the drug book.
• RADV rule vacated (Sept 2025) — a Humana-led challenge struck down the 2023 contract-wide-extrapolation audit rule in N.D. Texas; clawback risk delayed, not removed.
• MaxHealth acquisition (Feb 2026) and continued CenterWell build-out.
• The tape turned (mid-2026) — after bottoming ~$185 in early 2026, the stock rallied to ~$350 on “softer medical cost trends” and sector-wide optimism (+30.6% since the last earnings print, +6% on June 4, 2026).

Verdict: On balance these strengthen the forward thesis (new disciplined management, the worst of the Star/utilization news arguably behind, supply-side discipline industry-wide) — but they also crystallize the structural headwinds (v28, IRA, the Star drag locked in through PY2026) and the fact that the market has already re-rated the stock to reflect the better news.

9. Risk Analysis (Risk Matrix)

The dominant risks cluster around the benefit-ratio recovery path, Star-ratings timing, and CMS policy — all of which feed the central valuation question of whether the back-end-loaded recovery embedded at ~$350 is achievable. Catastrophic loss is remote; the realistic downside is a re-rating back toward the $200s, not impairment.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — embedded expectations and scenario zones only.

10.1 Multiples — why trailing P/E misleads

Trailing P/E at the 98th percentile is a denominator illusion; the relevant question is normalized earnings power.

10.2 Peer comparison (forward P/E)

CI ~8.6x · CVS ~11.5x · CNC ~14x · ELV ~14.2x · UNH ~19x · MOH ~21x · HUM ~22x. Humana screens as the richest managed-care name on forward earnings (tied with equally-troughed Molina) — the market is paying up for the steepest recovery slope.

10.3 Embedded expectations — the core

Reverse-engineering ~$350 (~$42B market cap) at a normal managed-care multiple of 13–16x implies a normalized EPS of ~$22–27 (midpoint ~$24). Put in context:

• That is above the FY2023 pre-trough peak (~$20 GAAP),
• well above FY2027 consensus (~$15–15.43),
• and ~35% below management’s old ~$37 adjusted aspiration.

So at $350 the market underwrites a near-full return to the structurally-re-rated prior-peak earnings power by roughly 2028 — benefit ratio falling from 90.2% to the mid-to-high-80s, individual-MA pretax margin to ~3%, ROE from ~7% back to the mid-teens, and the Star drag largely repaired. The $185→$350 move converted Humana from “trough priced as permanent” (a convex deep-value setup) into “recovery priced as largely assured.” Tellingly, the sell-side consensus target (~$269) and even some bull-case targets ($254) now sit below the share price — the rally outran the analysts.

10.4 Scenario zones (not targets)

The base case is already paid for at $350. The convex deep-value asymmetry that existed at $185 has largely been harvested; from here the payoff is more symmetric — modest upside to the base/bull, real downside to the bear if the recovery slips or CMS harvests it.

10.5 What the market gets right vs. wrong

• Likely right: FY2026 is the earnings trough; the cyclical (utilization + 2025-rate) piece of the recovery is real; the strong 2026 rate and supply discipline help survivors.
• Possibly wrong: the timing and magnitude — the implied ~$24 normalized EPS leans heavily on a 2028 back-end; the structural floor may be deeper (capping normalized EPS in the high-teens); and the Star drag is locked in through PY2026 with only guidance (not fact) of PY2027 relief.

Verdict: At ~$350, embedded expectations sit near the base case — a near-full, structurally-re-rated recovery by ~2028. The risk/reward, so convex at $185, is now roughly balanced. The variant-perception fulcrum is whether the market is pricing the ~40% structural piece correctly or underwriting a fuller cyclical snap-back.

11. Variant Perception

Consensus belief: FY2026 is the trough; Humana is a high-quality MA franchise whose margins normalize into 2027–28; the stock has re-rated to reflect this, and the sell-side (target ~$269) is now behind the market, with the share price having overshot prior targets on cost-trend optimism.

Strongest bull case: A scale #2 incumbent in a secularly-growing, supply-disciplined industry, at a genuine earnings trough that is ~60% cyclical. Insiders bought into the decline; a new, disciplined management is fixing Stars and margins; the strong 2026 rate (+9% effective) is a powerful 2027 tailwind; CenterWell is a scaling payvider option. If the benefit ratio returns to the mid-80s and Stars recover top-quartile, normalized EPS pushes toward $30–37 and the stock has a clear path to the $470–600 zone — and the structural-bears are over-discounting a fixable, cyclical problem.

Strongest bear case: A pure-play with no diversification and no real moat (management concedes barriers “are not substantial”), ~83% dependent on a single buyer that is systematically taking margin back (v28, IRA, MedPAC’s $84B overpayment critique, RADV, prior-auth limits). The Star collapse is self-inflicted and locked in through PY2026; the recovery is back-end-loaded to 2028; reported margins are propped by reserve releases and tax help while the cushion (DCP) thins; capital allocation is mid-pack with a $3–5B WCAS put overhang. And the stock has already doubled — so you are paying a full recovery multiple (richest in the group) for a structurally-disadvantaged business whose recovery the regulator can cap at will. Downside to the $200s if anything slips.

The 3–5 assumptions that matter most:

1. The benefit-ratio recovery path (does it reach the mid-to-high-80s by 2027–28?).
2. Star-ratings recovery timing (does PY2027 actually deliver bonus relief?).
3. The cyclical/structural split of the margin compression (is it ~60/40 or worse?).
4. The 2027 CMS rate notice (does the monopsony harvest the recovery?).
5. Whether normalized EPS is ~$24 (base, justifying $350) or high-teens (structural, justifying the $200s).

What would falsify each side: The bull is falsified by a benefit ratio stuck at ~90%+ through 2027, a soft 2027 rate notice, or a re-promulgated RADV clawback. The bear is falsified by a clean BR inflection below ~88% in 2026–27 with visible Star recovery for PY2027 and CenterWell margin scaling.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the true normalized benefit ratio once the BY2026 Star headwind laps, the 2026 membership cohort seasons, and prior-year reserve development normalizes? FY2025’s 90.2% was aided by ~$1.0B of development; run-rate may be ~91%.
2. Does Star-ratings recovery actually arrive for PY2027, and is the bonus economics recoverable on management’s timeline? (Currently guidance, not fact.)
3. The 2027 CMS Advance Notice (issued ~Jan 2026) — recovery-supportive or renewed harvesting?
4. RADV re-promulgation — timing, probability, and extrapolated-clawback magnitude after the Sept 2025 vacatur.
5. Precise structural-vs-cyclical dollar split of the MLR step-down — sizes the gap between the bear (~high-teens EPS) and the implied (~$24).
6. WCAS put/call — will Humana be forced into a $3–5B buyout, and when; how dilutive to capital return?
7. CenterWell true economics ex-intersegment transfer pricing — is it incrementally profitable or a strategic loss-leader?
8. Days-claims-payable decline (~42→33) — benign adjudication speed-up or thinning reserve adequacy ahead of still-elevated trend?

14. What Must Be True

For the bull case (recovery justifies/exceeds $350):

• The consolidated benefit ratio must fall to the mid-to-high-80s by 2027–2028 (from 90.2%).
• Star ratings must recover meaningfully for PY2027, restoring $1–3B of bonus revenue.
• The 2027+ CMS rate environment must remain at least neutral (not harvest the recovery).
• Normalized EPS must reach ~$25–30+, validating a 13–16x multiple at or above today’s price.
• Falsification test: If the FY2026–FY2027 benefit ratio fails to break below ~88% on a clean (ex-reserve-release) basis, or the PY2027 Star ratings do not improve, the normalized-EPS bridge to ~$24+ breaks and the stock is overvalued at $350.

For the bear case (structural impairment; fair value in the $200s):

• The margin compression must prove more structural than cyclical (v28/IRA/coding cuts permanently capping normalized EPS in the high-teens).
• CMS must continue extracting margin (soft rates, re-promulgated RADV, MedPAC-driven coding cuts).
• The Star drag and back-end-loaded recovery must disappoint on timing.
• Falsification test: If Humana posts a clean benefit-ratio inflection below ~88% in 2026–27 with visible Star recovery and CenterWell margin scaling, the structural-impairment thesis is wrong and normalized EPS pushes toward $30+, supporting the bull zone.

15. Source Appendix (summary)

Primary sources (full citations in Appendix B): Humana FY2023/FY2024/FY2025 Forms 10-K (filed 2024-02-15, 2025-02-20, 2026-02-19) and Forms 10-Q through Q1 2026 (filed 2026-04-29); the 36-month 8-K and Form 3/4/5 corpus (SEC EDGAR, CIK 0000049071); the 2026 DEF 14A proxy. Quantitative reconciliation via SEC EDGAR XBRL and public market-data aggregators. Industry/regulatory: CMS 2025/2026 Rate Announcements; CMS-HCC v28 documentation; MedPAC reports; KFF Medicare Advantage 2025/2026 enrollment and insurer-financial-performance analyses; RADV final rule and the Sept 2025 N.D. Texas vacatur; Star-ratings coverage (Healthcare Dive, Fierce Healthcare, Becker’s). The body of this memo states no recommendation and no price target; the sole position is in the fenced “Claude’s Take” block, which is the author’s own independent view.

Appendix A — Diligence Questionnaire

Humana Inc. (NYSE: HUM) — supplemental to the research memo Prepared: June 6, 2026 · Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates: (1) Is this earnings trough cyclical or a permanent re-rating of the MA profit pool? — the single most important question, and the one that splits bulls from bears. (2) Is the Star-ratings collapse self-inflicted and fixable, or symptomatic of operational decay? (3) Can CenterWell ever reach Optum-like scale, or is it a perpetual sub-scale also-ran? (4) Given ~83% federal/~70% MA concentration, is Humana investable at all without diversification? (5) After the $185→$350 rally, is there any margin of safety left? (6) How clean are the “adjusted” earnings, given $7.38/share of FY2025 add-backs? (Interpretation, synthesized from sell-side and sector analysis.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Low — a clear trough. (Fact) GAAP diluted EPS fell from $20.00 (FY2023) to $9.84 (FY2025); the benefit ratio rose to 90.2% and ROE to ~7% from ~16%. FY2026 GAAP guidance is ~$9 — the bottom.

Driven by the external environment or internal actions? Both. (Interpretation) External: post-COVID utilization, soft 2025 CMS rates, v28 risk-model phase-in, IRA Part D. Internal/self-inflicted: the Star-ratings collapse (operational miss on quality measures) and the deliberate 2025 membership prune. The apportionment is ~60% external-cyclical / ~40% structural+idiosyncratic.

How stable are revenues? Revenue is stable-to-growing at the aggregate level ($106B→$130B FY23→25), but the figure is distorted upward by IRA Part D gross-up accounting. (Fact) Member-level revenue is not stable — annual AEP switching and the 2025 prune produced double-digit membership swings.

Outlook for products/services? MA: secular volume growth, margin recovery the swing factor. (Interpretation) CenterWell: high-growth (external primary-care revenue +76% YoY). PDP: structurally less attractive post-IRA. Medicaid/specialty: stable, low-margin.

How big will this market be — growing, shrinking, domestic or international? Growing, domestic. (Fact) US MA penetration 54% of eligible Medicare (2025) → ~64% by 2034 (CBO). Entirely domestic. The demand tailwind is one of the best in US healthcare; the constraint is profit-pool extraction by CMS, not demand.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More competitive on margin, less on capacity. (Interpretation) Supply is exiting (UNH/HUM county exits, −10% plan count for 2026), which helps survivors; but CMS is squeezing the profit pool for everyone, so per-member margin competition intensifies.

How profitable is the business (ROIC, ROE)? ROE ~7% at the trough vs. ~16% normalized; ROIC not meaningful for an insurer (float/regulatory capital distort the denominator). (Fact)

How profitable is the industry — how many competitors, barriers to entry? MA is the highest-margin insurance line (~$1,655/enrollee 2024, down from ~$1,982) but compressing. (Fact) A two-firm national oligopoly (UNH+HUM ~46%) with deep local concentration — yet management concedes “barriers to entry in our markets are not substantial.” (Fact, FY2025 10-K) Local scale is real; durable pricing power is not, because CMS sets the price.

Can the business be easily understood? Yes. (Interpretation) An MA underwriting spread (CMS capitation minus medical cost) plus an owned-care-delivery arm. The complexity is regulatory (rate notices, v28, Stars, RADV), not operational.

Can it be undermined by foreign low-cost labor? No. (Fact) Domestic, regulated, service-delivery business.

Do brands matter? Modestly. (Interpretation) The Humana brand aids retention and acquisition but does not prevent free annual switching or county entry. Weak-to-moderate intangible.

What is the nature of competition? Annual benefit/price competition for senior enrollees during AEP, plus competition for provider networks and for Star-ratings performance (which funds richer benefits). (Fact)

Customers’ switching costs? Near zero. (Fact) Seniors switch plans for free every AEP — the central weakness of the moat.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The CenterWell care-delivery platform and MA distribution franchise carry intangible value beyond book; conversely, statutory excess capital (~$14.1B vs. ~$6.9B minimum) is real balance-sheet strength. (Interpretation/Fact)

Off-balance-sheet liabilities? The WCAS put/call on the CenterWell primary-care JV is the key item — puttable to Humana 2027–2034, potentially requiring $3.0–5.0B (a contingent quasi-acquisition liability WCAS can force in a down market). (Fact, 10-K Notes 4/6) Also routine medical-claims-incurred-but-not-reported reserves (on balance sheet, but estimate-driven).

How conservative is the accounting? Mixed. (Interpretation) Reserves: favorable prior-year development every year (peaking ~$1,029M FY2025) propping reported margins while days-claims-payable thinned ~42→33 days — less conservative on the margin. “Adjusted” EPS add-backs ($7.38/share FY2025, incl. four-years-running “value creation” restructuring) are aggressive. GAAP is the honest spine.

How CapEx-hungry is the business? Light. (Fact) Capex ~$0.5B/year (CenterWell clinic build-out); the insurance business is capital-light operationally but capital-intensive in regulatory terms (statutory reserves).

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy? Insurer “FCF” is better read as operating cash flow ($921M FY2025, depressed by CMS-payment timing) and subsidiary dividends upstreamable to the parent ($1.1B in 2025, declining from $1.8B). (Fact) Use: a frozen dividend (~$3.54/share, ~1% yield) and — until paused — buybacks. Philosophy under Rechtin: margin over membership, deleveraging, capital-return restraint while subsidiary cash is constrained. (Interpretation)

Significant acquisitions recently? MaxHealth (Feb 2026, ~$908M, ~88% goodwill — a CenterWell tuck-in into the trough). (Fact) Historically: Kindred at Home buy-in (2021, ~$8.2B EV at a peak — has produced impairments). Divestitures: 60% of Gentiva (2022, good harvest) and the commercial-employer-group exit (2025, disciplined).

Buying back shares? Effectively paused (FY2025 ~0.4M shares; ~$2.7B authorization unused) after buying ~$4.7B FY2021–25 concentrated at the 2023–24 peak (~$483/$385). (Fact) Bought high, paused at the bottom — poor sequencing.

Issuing large amounts of new shares to insiders? No meaningful dilution; SBC modest (~0.6% of revenue); shares ~flat. (Fact)

Compensation policy of directors/management? Annual incentive 70% adjusted EPS (target $37) + 30% strategic, rTSR modifier — the dominant metric is gameable. Long-term incentive redesigned (2025) to rTSR 50% / Stars 30% / productivity 20% — a genuine improvement. (Fact, 2026 DEF 14A)

Motivations of management? Insider ownership trivial (~0.20%; CEO below his 7x guideline) — an alignment weakness. (Fact) But insider behavior into the drawdown was constructive: three open-market buys (CEO Rechtin $1.5M @ $229; CenterWell president Shetty @ $185; director Mesquita @ $367) and only one small sale in 36 months. (Fact, Form 4 filings)

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — a US common-stock C-corp (NYSE: HUM); standard 1099 treatment. (Fact)

Dividend policy? Quarterly cash dividend frozen at $0.8850 (~$3.54/year, ~1% yield) since 2024; conservative payout while earnings are depressed. (Fact)

How profitable is the business? Trough operating margin ~2.1% (FY2025) vs. ~3.8% (FY2023); normalizing toward mid-single-digits as the benefit ratio recovers. (Fact/Interpretation)

Is net income diverging from cash from operations? Yes, but benignly — FY2025 OCF ($921M) fell below net income (~$1.19B) due to CMS-payment-timing/float and reserve runoff, not earnings quality. (Fact) Do not apply an FCF framing to an insurer.

Risks & Downside

What factors would cause the stock to decline? Benefit ratio stuck at ~90%+ into 2027; no Star recovery for PY2027; a soft 2027 CMS rate notice; re-promulgated RADV extrapolation/coding clawback; a WCAS put forcing a large buyout; the back-end-loaded (2028) recovery slipping. (Interpretation, from the risk matrix)

Risk of a catastrophic loss? Low. (Interpretation) Strong statutory capital (~2x minimum), a diversified member base, and no debt-maturity wall make solvency-threatening loss remote. The realistic downside is a valuation re-rating back toward the $200s, not impairment.

Chance of a total loss? Negligible. (Interpretation) This is an investment-grade, systemically-embedded health insurer; total loss is not a credible scenario absent fraud or an extreme, unprecedented regulatory event.

Recent News & Events

Has the business environment changed recently? Yes — materially, and recently for the better. (Fact) After bottoming ~$185 in early 2026, the stock rallied ~doubled to ~$350 on “softer medical cost trends” and sector-wide optimism (+30.6% since the last earnings print, +6% on June 4, 2026). The strong 2026 CMS rate (+9% effective) is a tailwind into 2027. (Interpretation) The improvement is real but largely priced.

Significant acquisitions? MaxHealth (Feb 2026, ~$908M). (Fact)

Change in accounting policies? IRA Part D gross-up inflates reported premium/revenue (presentation, not economics). (Fact) No aggressive policy change identified, but watch the growing adjusted-EPS add-backs.

Recent changes — new markets, facilities, management? Near-total C-suite reset (CEO Rechtin July 2024 + new CFO/CHRO/CIO/MA-president); deliberate exit of ~198 counties and the commercial-employer-group line for 2026; CenterWell mail-order pharmacy capacity expansion (June 2026); MaxHealth clinic platform added. (Fact)

Appendix B — Source Appendix

Humana Inc. (NYSE: HUM) — sources underpinning the research memo and diligence appendix Compiled: June 6, 2026. Primary sources first. All web sources accessed 2026-06-06 unless noted.

1. Primary — SEC filings (EDGAR, CIK 0000049071)

Key data extracted (with period):

• Benefit (medical-loss) ratio: 87.3% (FY2023) / 89.8% (FY2024, +250bps) / 90.2% (FY2025); Insurance segment 88.0%/90.4%/90.4%; Q1 2026 89.4% vs. Q1 2025 87.0% — MD&A, each 10-K/10-Q.
• GAAP diluted EPS: $20.00 / $9.98 / $9.84 — consolidated income statements.
• Revenue: $106.4B / $117.8B / $129.7B; individual MA ~70.3% of FY2025 revenue; total Medicare ~82.6%; ~83% premium from federal government — segment/revenue tables.
• Adjusted-EPS reconciliation: add-backs $5.59 / $4.93 / $7.38 per share (FY23/24/25); FY2025 = put/call marks $4.25 + “value creation” restructuring $3.72 + impairments $2.09 — non-GAAP reconciliation.
• Prior-year reserve development (favorable): ~$872M (FY23) / ~$701M (FY24) / ~$1,029M (FY25); benefits payable $10.24B/$10.44B/$9.97B; DCP ~42→~33 days — Notes.
• Cash flow: OCF $3,981M/$2,966M/$921M; capex ~$1.0B/$0.6B/$0.5B; subsidiary dividends to parent $1.8B/$1.5B/$1.1B; statutory capital ~$14.1B (YE25) vs. ~$6.9B minimum — liquidity/statutory sections.
• Balance sheet: equity $16.3B/$16.4B/$17.7B (→$18.6B Q1’26); goodwill $9.55B→$9.69B→$10.49B (Q1’26, MaxHealth); LT debt $11.1B→$12.4B — balance sheet + Notes.
• Buybacks: ~$4.7B cumulative FY2021–25 (FY23 ~3.1M sh @ ~$483; FY24 ~1.9M @ ~$385; FY25 ~0.4M @ ~$234); ~$2.7B authorization unused — Note 16.
• Risk Factors verbatim: “barriers to entry in our markets are not substantial… customers enjoy significant flexibility in moving between competitors through the Annual Enrollment Period” — FY2025 10-K Item 1A.
• MaxHealth acquisition: ~$908M cash (~$800M goodwill), closed 2026-02-13 — Q1 2026 10-Q Note 3.
• WCAS CenterWell primary-care JV put/call (146 clinics): call 2026–2033, put to Humana 2027–2034, potentially $3.0–5.0B — 10-K Notes 4/6.
• Insider open-market purchases (code P, non-10b5-1): CEO Jim Rechtin 6,530 sh @ $229.25 (~$1.5M, 2025-05-14); Sanjay Shetty (President CenterWell) 810 sh @ $185.21 (2026-02-23); director Jorge Mesquita 545 sh @ $367.09 (2024-02-20); only one small discretionary sale (Huval, CAO) in 36 months — Form 4 filings.
• Proxy incentive design: AIP 70% adjusted EPS (target $37.00) + 30% strategic + rTSR modifier; 2025 LTI redesigned to rTSR 50% / Stars 30% / productivity 20%; insider ownership ~0.20% — 2026 DEF 14A.

2. Primary — quantitative reconciliation

• SEC EDGAR XBRL (CIK 0000049071): Revenues, NetIncomeLoss, EarningsPerShareDiluted, WeightedAverageNumberOfDilutedSharesOutstanding, StockholdersEquity, Goodwill, LiabilityForClaimsAndClaimsAdjustmentExpense, NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment. Accessed 2026-06-06.
• Public market-data aggregators (reconciled to filings): price ~$350, market cap ~$42B, EV ~$45B, forward P/E ~22x, peer multiples. Accessed 2026-06-05/06.
• Own-history valuation percentiles (public market data): price $350.08, ttm_eps $9.3435, BVPS $153.9966, P/E 37.47 (98.0th pctile own history), P/B 2.27 (20.2th), P/S 0.31 (16.6th); short interest 5.67% of float; analyst mean target $269.375. Accessed 2026-06-05.

3. Industry & regulatory (third-party, primary-adjacent)

• CMS — 2026 MA & Part D Rate Announcement (final +5.06%, +9.04% effective; released 2025-04-07) and 2025 Rate Announcement (final +3.70%, +2.33% effective), cms.gov.
• CMS-HCC v28 risk-model documentation — phase-in 33%/67%/100% (PY2024–26), ~−3.12% avg risk score, ICD 9,797→7,770, HCC 86→115 (riskadjustmentmodel.com; medinsight.com; MedPAC comment letter).
• MedPAC — MA overpayment estimate ~$84B (~20% above FFS) 2025 (~$40B coding intensity + ~$44B favorable selection), ~$76B 2026 (via Becker’s Payer, Healthcare-Brew, Fierce Healthcare).
• RADV — 2023 final rule (contract-wide extrapolation, FFS-Adjuster eliminated, ~$4.7B clawback est. through 2032); vacated 2025-09-25, N.D. Texas (Humana-led challenge) on APA grounds (Fierce Healthcare; Groom Law; Milliman; Becker’s).
• KFF — “Medicare Advantage in 2025: Enrollment Update and Key Trends” (54% penetration, 34.1M/62.8M, CBO 64% by 2034, ~4% growth, UNH+HUM ~46%); “Most MA Markets are Dominated by One or Two Insurers” (2/3 of counties; 9-in-10 concentration); “Health Insurer Financial Performance 2023/2024” (MA gross margin/enrollee series, ~90% MLR 2024); “MA 2026 Spotlight” (plan count −10%, 3,719→3,373), kff.org.
• Star ratings — Humana 4+ star membership ~94%→25%→~20% (PY2024→26), avg 4.37→3.63→3.61; contract H5216 4.5★→3.5★; Humana lost the CMS lawsuit twice, appeal denied; 14% of members into 4.5+ star plans for 2026 (Healthcare Dive; Fierce Healthcare; Becker’s Payer; Healthcare-Brew).
• 2026 county exits — UNH ~225, Humana ~198 counties; HUM −3 states / ~500K members affected (Healthcare Dive, “UnitedHealthcare, Humana, Aetna scale back MA plans for 2026”).
• IRA Part D redesign — $2,000 OOP cap (2025)/$2,100 (2026); insurer catastrophic-liability shift (CMS Part D Redesign fact sheets; Health Affairs; ASPE).
• Valuation context — FY2026 GAAP guide “at least $9.00” (HUM Q1 2026 8-K); FY2027 consensus ~$15–15.43; 2028 bull-case ~$25+; Piper PT $254; consensus ~$269 (247wallst.com 2026-05-13; ainvest.com; tikr.com; investing.com/Evercore); healthcare EV/EBITDA median ~11.5x (focusbankers.com).

4. News & sentiment (third-party signal — validated against primary sources)

• Recent news coverage (accessed 2026-06-06): HUM “+30.6% since last earnings report,” +6% on 2026-06-04 (“softer medical cost trends”), sector-wide bullish notes (UNH/CVS/CI), “HMO stocks in focus / aging population.” Sentiment signals treated as signal, not evidence, and validated against primary sources.

5. Analytical frameworks

• Greenwald & Kahn, “Competition Demystified” (barriers-to-entry taxonomy, share-stability/ROIC tests) and Marathon Asset Management, “Capital Returns” (supply-side capital cycle, asset-growth anomaly). Applied in the industry, competitive-position, and capital-allocation analysis.